Table 1.
Clinicopathological features of metaplastic breast carcinoma, invasive ductal carcinoma and triple-negative invasive ductal carcinoma
| |
Metaplastic breast cancer (N = 55) |
Invasive ductal carcinoma (N = 767) |
TN-IDC (N = 131) |
||
|---|---|---|---|---|---|
| Features | N (%) | N (%) | P | N (%) | P |
|
Age |
|
|
0.594 |
|
0.264 |
| ≤50 |
27 (49.09) |
405 (52.80) |
|
76 (58.02) |
|
| >50 |
28 (50.91) |
362 (47.20) |
|
55 (41.98) |
|
|
Stage |
|
|
0.001 |
|
<0.001 |
| I |
4 (7.27) |
107 (13.95) |
|
21 (16.03) |
|
| II |
30 (54.55) |
522 (68.06) |
|
92 (70.23) |
|
| III |
16 (29.09) |
87 (11.34) |
|
8 (6.11) |
|
| Unknown |
5 (9.09) |
51 (6.65) |
|
10 (7.63) |
|
|
Operation |
|
|
0.051 |
|
0.054 |
| Breast-conserving surgery |
4 (7.27) |
134 (17.47) |
|
25 (19.08) |
|
| Modified radical mastectomy |
51 (92.73) |
633 (82.53) |
|
106 (80.92) |
|
|
Chemotherapy |
|
|
0.302 |
|
0.295 |
| Yes |
48 (87.28) |
627 (81.74) |
|
106 (80.91) |
|
| No |
7 (12.73) |
140 (18.25) |
|
25 (19.08) |
|
|
Radiotherapy |
|
|
<0.001 |
|
<0.001 |
| Yes |
27 (49.09) |
177 (23.08) |
|
29 (22.14) |
|
| No |
28 (50.91) |
590 (76.92) |
|
102 (77.86) |
|
|
Hormone therapy |
|
|
<0.001 |
|
|
| Yes |
13 (23.64) |
522 (68.06) |
|
— |
|
| No |
42 (76.46) |
245 (31.94) |
|
— |
|
|
Pathological tumor stage |
|
|
<0.001 |
|
<0.001 |
| T1 (≤2 cm) |
5 (9.09) |
317 (41.33) |
|
58 (44.27) |
|
| T2 (2–5 cm) |
22 (40.00) |
332 (43.29) |
|
55 (41.98) |
|
| T3 (>5 cm) |
22 (40.00) |
39 (5.08) |
|
5 (3.82) |
|
| Tx |
6 (10.91) |
79 (10.30) |
|
13 (9.92) |
|
|
Pathological nodal stage |
|
|
0.001 |
|
0.001 |
| N0 |
35 (63.64) |
314 (41.20) |
|
50 (38.17) |
|
| N1-3 |
15 (27.27) |
385 (49.93) |
|
69 (52.67) |
|
| Nx |
5 (9.09) |
68 (8.87) |
|
12 (9.16) |
|
|
Histological grade |
|
|
0.167 |
|
0.285 |
| I or II |
29 (52.73) |
461 (60.10) |
|
77 (58.78) |
|
| III |
20 (36.36) |
227 (29.60) |
|
41 (31.30) |
|
| Unknown |
6 (10.91) |
79 (10.30) |
|
13 (9.92) |
|
|
Ki-67a |
|
|
<0.001 |
|
<0.001 |
| ≥14% |
47 (87.27) |
486 (63.36) |
|
80 (61.07) |
|
| <14% |
8 (12.73) |
281 (36.64) |
|
51 (38.93) |
|
|
P53b |
|
|
0.001 |
|
0.008 |
| ≥25% |
28 (50.91) |
221 (28.81) |
|
40 (30.53) |
|
| <25% |
27 (49.09) |
546 (71.19) |
|
91 (69.47) |
|
|
Estrogen receptor |
|
|
<0.001 |
|
|
| + |
8 (14.55) |
419 (54.63) |
|
— |
|
| − |
47 (85.45) |
348 (45.37) |
|
— |
|
|
Progesterone receptor |
|
|
<0.001 |
|
|
| + |
10 (18.18) |
492 (64.14) |
|
— |
|
| − |
45 (81.82) |
276 (35.98) |
|
— |
|
|
Human epidermal growth factor receptor-2 |
|
|
0.005 |
|
|
| + |
9 (16.36) |
268 (34.94) |
|
— |
|
| − |
46 (83.64) |
499 (65.06) |
|
— |
|
|
TN-MBC |
37 (67.27) |
131 (18.22) |
<0.001 |
— |
|
| Not TN-MBC | 18 (32.73) | 636 (81.78) | — | ||
aMedian value for Ki-67 = 13.96, bMedian value for P53 = 24.85. TN-MBC, triple-negative metaplastic breast carcinoma; TN-IDC, triple-negative invasive ductal carcinoma.